(OMER)
NGM – Real vaqt narxi. Valyuta: USD
9.88
-0.42 (-4.08%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
9.86
-0.02 (-0.20%)
Bozordan keyin: Mar 27, 2026, 7:47 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
9.88
-0.42 (-4.08%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
9.86
-0.02 (-0.20%)
Bozordan keyin: Mar 27, 2026, 7:47 PM EDT
Omeros Corporation, klinik bosqichdagi biotexnologiya kompaniyasi, immunologik kasalliklarga qarshi kichik molekulalar va oqsil terapiyasini kashf etadi, ishlab chiqadi va tijoratlashtiradi, shuningdek, o'rtacha ko'rsatkichlarni maqsad qiladi. Kompaniyaning asosiy mahsulot nomzodlaridan biri bu gemopoetik ildiz hujayralari transplantatsiyasi bilan bog'liq trombotik mikroangiopatiyani (TA-TMA) davolash uchun Narsoplimab (OMS721/MASP-2); va COVID-19 va o'tkir respirator distress sindromini davolash uchun II bosqich klinik sinovlaridan o'tmoqda. Kompaniya, shuningdek, mannan-bog'lovchi lektin-bog'liq serin proteaza 2 (MASP-2) va lektin yo'li buzilishlari uchun I bosqich klinik sinovlarini tugatgan OMS1029ni ishlab chiqmoqda; Paroksismal tungi gemoglobinuriyani davolash uchun III bosqich klinik sinovlarida bo'lgan zaltenibart; komplement 3 glomerulopatiyani va boshqa muqobil yo'l buzilishlarini davolash uchun II bosqich klinik sinovlarida; va giyohvandlik va majburiy buzilishlar, harakat buzilishlari, shuningdek, kokaindan foydalanish buzilishlari uchun I bosqich klinik sinovlarida bo'lgan OMS527. Bundan tashqari, kompaniyaning preklinik rivojlanish bosqichidagi mahsulotlari lektin yo'li buzilishlarini davolash uchun yallig'lanishga qarshi oqsil bo'lgan MASP-2; muqobil yo'l buzilishlari uchun MASP-3 kichik molekulali ingibitorlari; va turli xil saraton turlarini davolash uchun Adoptiv T-hujayrali va Immunostimulyator Kombinatsiyalangan Terapiyalari, Onkotoksinlar va Immunomodulyatorlar. Omeros Corporation 1994 yilda tashkil etilgan va shtab-kvartirasi Vashington shtatining Sietl shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andreas Grauer M.D. | VP & Chief Medical Officer |
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science |
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder |
| Mr. David J. Borges | VP of Finance, Chief Accounting Officer & Treasurer |
| Mr. David W. Ghesquiere | VP & Chief Business Development Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-07 | 8-K | omer20260107_8k.htm |
| 2025-12-29 | 8-K | omer20251218_8k.htm |
| 2025-12-01 | 8-K | omer20251024_8k.htm |
| 2025-11-13 | 8-K | omer20250825_8k.htm |
| 2025-10-15 | 8-K | omer20251014_8k.htm |
| 2025-08-14 | 8-K | omer20250521_8k.htm |
| 2025-07-25 | 8-K | tm2516030d4_8k.htm |
| 2025-07-02 | 8-K | omer20250624_8k.htm |
| 2025-05-30 | DEF 14A | edge20044753x1_def14a.htm |
| 2025-05-16 | 8-K/A | omer20250515_8ka.htm |
| Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary |
| Mr. Peter W. Williams | Vice President of Human Resources |
| Ms. Nadia Dac | VP & Chief Commercial Officer |